The FDA this week posted an untitled letter sent Oct. 17 to China-based active pharmaceutical ingredient (API) ...
GSK is leaving the biopharma trade group BIO, a spokesperson confirmed, the latest large pharma to back out of the ...
Amgen and AstraZeneca said on Friday that their asthma drug Tezspire reduced nasal congestion and the size of nasal ...
Eisai has slashed Leqembi's sales forecast by 25% this year, lowering the ceiling for one of the industry's most ...
In another sign that biopharma companies are slowing their early R&D efforts, Charles River Laboratories is shuttering more than a dozen sites. The service provider is working on “consolidating ...
Nkarta is punting development of a natural killer cell therapy in cancer to focus instead on the same candidate's prospects ...
Stephen Squinto, recruited by JP Morgan a few years ago to head up its Life Sciences Private Capital team, is raising a ...
The head of AstraZeneca’s operations in China has been detained by authorities there, the company confirmed. Prior to his ...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Coherus is resuming the supply of its ...
Aurinia Pharmaceuticals is reducing 45% of its workforce and is bringing in a new board member as part of a broader restructuring. The company ...
Denali revealed new topline data Wednesday for an early-stage program that's a part of the FDA’s Operation Warp Speed for rare diseases. The program, DNL126, is an ...
After a year of customer pullbacks, biologics CDMO Avid Bioservices will be taken private by GHO Capital Partners and Ampersand Capital Partners in a deal worth $1.1 billion. “In evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback